Drug intelligence / Profile preview

Ad-COX2-E1a

Development stage: Preclinical
Lead developer: Kobe University Graduate School of Medicine
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral, Potentially Intravenous (typically Experimental)

Overview

Ad-COX2-E1a is a **replication-selective adenoviral vector** in which the expression of the adenoviral E1a gene—required for viral replication—is controlled by the **cyclo-oxygenase 2 (COX-2) promoter**. The drug is designed for **oncolytic therapy**: it selectively replicates in and destroys tumor cells that express COX-2, such as squamous cell carcinoma of the head and neck[1]. By driving E1a expression with the COX-2 promoter, replication occurs preferentially in COX-2–positive cells, limiting activity in normal tissues.

Other names: Ad-COX2-E1aAd-COX-2-E1aAd-COX 2-E1a

Targets

E1A (Adenovirus early region 1A protein)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Ad-COX2-E1a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad-COX2-E1a.

Explore the full profile